-
Clinical Trials & Development6 days agoNovo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a molecule that analysts had once tipped as...
-
Clinical Trials & Development7 days agoIntegration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment
Nature Biotechnology, Published online: 07 September 2026; doi:10.1038/s41587-026-03286-ySix proteomic clocks are applied in a clinical trial to assess anti-aging effects.
-
Clinical Trials & Development7 days agoEmotional Changes in Chronically Ill Patients After a Complementary Therapy Support Program
When patients living with long-term illnesses such as cancer, diabetes, or chronic pain walk through the doors of a hospital workshop dedicated to painting, music, relaxation,...
-
Clinical Trials & Development1 week agoTreating osteoporosis in older men: review of drug and lifestyle trials
Osteoporosis has long been framed as a disease of older women, but a new systematic review of randomized controlled trials is drawing attention to a population...
-
Clinical Trials & Development1 week agoStaff perspectives shape cross-sector care for dual diagnosis patients
Mental health services in Denmark are testing whether a simple but demanding promise—no patient with co-occurring mental illness and substance use disorder should ever be turned...
-
Clinical Trials & Development1 week ago
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
ADARx has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA...
-
Clinical Trials & Development1 week agoFrench expert consensus on cladribine tablets for relapsing MS beyond year 4
French neurologists have published a pragmatic guide for one of the most pressing unanswered questions in modern multiple sclerosis care: what to do with patients who...
-
Clinical Trials & Development1 week agoTargeting tumor microenvironment cells: new directions in brain metastasis therapy
Brain metastases strike up to 30 percent of cancer patients, bringing headaches, seizures, neurological deficits and a median survival of only six to ten months. Yet...
-
Clinical Trials & Development1 week ago
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win
Roivant’s $14 million bet on a pulmonary hypertension drug from Bayer appears to have paid off as the inhaled med aced a phase 2 lung disease...
-
Clinical Trials & Development1 week agoNovartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for...
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
